Saturday 17 October 2026
Export GNPX’s income statement to Excel — free account
GENPREX
GNPX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 95.0% and free cash flow fell 33.0%, each against the same quarter a year earlier.
2.11
0.18
−7.86%
Follow GNPX
GENPREX (GNPX) P/E ratio
As of 16 October 2026, GENPREX (GNPX) trades at a P/E ratio of 0.0×. Over the past ten years it has ranged from 0.0× (June 2026) to 0.4× (October 2025); the current reading is higher than 92% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.4×
Ten-year median
0.0×
Current reading's percentile
92
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEXI NexImmune, Inc. compare | n/m |
| BRTX Biorestorative Therapies, Inc. compare | n/m |
| SILO Silo Pharma, Inc. compare | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| CLSDQ Clearside Biomedical, Inc. compare | n/m |
| TRVN Trevena, Inc. compare | n/m |
| GNPX GENPREX | 0.0× |
| OGEN Oragenics, Inc. compare | 0.4× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)